Editorials

ResMed reported full-year fiscal 2026 revenues of $5.65 billion, marking nearly 10% year-over-year growth in a mature but durable market. What makes the underlying picture worth examining is not the topline acceleration, but the consistent cash-conversion discipline that delivered $1.81 billion in operating cash flow while simultaneously returning $1.05 billion to shareholders through $700 million in buybacks and $350 million in dividends.

For a company operating primarily in sleep diagnostics and respiratory care, where devices and recurring subscription revenue dominate the mix, the execution is straightforward: grow revenue steadily, protect gross margin, and harvest the cash.

ResMed achieved gross profit of $3.45 billion on revenues of $5.65 billion, yielding a gross margin of 61.1%. This level of profitability reflects the mix of high-margin devices and even higher-margin recurring revenue from masks, diagnostics, and software subscriptions.

Broken down by segment, Sleep and Breathing Health generated $1.66 billion of the $5.65 billion revenue base, while Residential Care Software contributed $584 million. More tellingly, operating income split 92% to Sleep and Breathing ($1.68 billion) versus 8% to Residential Care ($154 million). The core sleep and respiratory business is the engine; the software division remains smaller and profitable but not dominant to the margin story.

Operating income totaled $1.89 billion against revenues of $5.65 billion, producing an operating margin of 33.4%. This consistency in margin structure across inflationary periods and competitive pressures suggests pricing power or cost discipline (or both) within the core portfolio.

Net income for FY2026 reached $1.52 billion, or $10.47 per share on a basic basis and $10.43 diluted. Year-over-year net income growth of 8.8%, slightly trailing the 9.85% revenue growth, reflects a modest operating leverage headwind or increased tax burden. Income tax expense totaled $396 million on pre-tax income of $1.92 billion, implying an effective tax rate of approximately 20.7%.

Earnings per share of $10.47 basic reflects a share count of roughly 145.4 million shares, consistent with the buyback program. The diluted EPS of $10.43 shows minimal dilution from options or other instruments, suggesting disciplined capital allocation through repurchases rather than dilution via acquisition-driven share issuance.

Operating cash flow of $1.81 billion represents 84% conversion of net income into cash, a healthy ratio for a capital-light software and medical-device hybrid. Quarterly distribution across FY2026 shows consistent cash generation: Q1 contributed $457 million, Q2 $340 million, Q3 $554 million, and Q4 $454 million, totaling the $1.81 billion.

Capital expenditure for acquisitions and plant/equipment totaled $546 million in investing activities (primarily the $351 million acquisition spend, plus smaller CapEx). Free cash flow on an operating basis thus sat approximately at $1.26 billion, or 83% of operating cash flow.

This cash generation enabled $700 million in share repurchases and $350 million in dividends while maintaining a cash balance of $1.47 billion on the balance sheet at fiscal year-end (down slightly from $1.66 billion in Q3, reflecting the Q4 buyback push of $200 million).

ResMed's balance sheet carries $2.91 billion in goodwill and $453 million in finite-lived intangible assets, totaling $3.36 billion in acquisition-related intangibles against total assets of $8.97 billion. Goodwill comprises approximately 32% of total assets, typical for a healthcare company with a history of tuck-in acquisitions (including the May 2025 VirtuOx diagnostic acquisition noted in the business profile).

Long-term debt stood at $399 million against $1.47 billion in cash, yielding net cash of $1.07 billion. Current liabilities of $1.40 billion included $309 million in accounts payable and $163 million in deferred customer revenue, suggesting solid customer prepayment momentum. Current assets of $4.32 billion, driven by $1.04 billion in net accounts receivable and $946 million in inventory, indicate working capital is well-managed for a medical-device distribution business.

During FY2026, ResMed returned $1.05 billion to shareholders via $700 million in share buybacks and $350 million in dividends, consuming roughly 58% of the $1.81 billion operating cash flow. This is neither reckless nor miserly; it reflects confidence in organic cash generation and a mature view of the business's competitive position.

Simultaneously, the company invested $351 million in acquisitions (net of cash), primarily the VirtuOx diagnostic platform, signaling continued belief in bolt-on consolidation within respiratory diagnostics. This dual commitment to shareholder returns and strategic M&A is sustainable if organic growth and margin remain stable.

The company traded at approximately $226.74 per share on August 13, 2026 (filing date), implying a market capitalization of $32.7 billion. Against FY2026 net income of $1.52 billion, this yields a P/E multiple of roughly 21.7x, slightly elevated but not punitive for a healthcare company with recurring revenue streams and mid-single-digit organic growth.

The enterprise value of approximately $31.9 billion divided by operating income of $1.89 billion suggests an EV/EBIT of 16.9x, or roughly 15.3x on an EV/EBITDA basis (factoring in $201 million in depreciation and amortization). These multiples reflect the market's pricing of ResMed as a steady, margin-stable compounder in the respiratory care and digital health space, not a high-growth technology play.

Price-to-book stands at approximately 4.97x on a book value of $45.65 per share, while tangible book per share of $22.34 yields a price-to-tangible-book multiple of 10.1x. The latter is notable, illustrating the premium the market assigns to the goodwill- and intangible-heavy capital structure.

ResMed's FY2026 10-K demonstrates a business that is doing what it is designed to do: convert recurring medical-device revenue into steady, predictable cash. Gross margin of 61% and operating margin of 33% are durable. Net income growth is tracking revenue growth, with minor leakage from tax and capital structure.

The core strength lies not in explosive growth, but in the recurring nature of masks, accessories, diagnostics, and software subscriptions layered atop a large installed base of cloud-connected devices and 30+ million active users.

The balance sheet is conservative with $1.07 billion in net cash. Share buybacks and dividends totaling $1.05 billion suggest management's confidence in the business's stability, though investors should monitor whether organic growth can sustain the current valuation multiples if competitive pressures intensify in respiratory care or if adoption rates in underpenetrated markets flatten.

The $351 million M&A spend on VirtuOx diagnostic capabilities signals a strategic belief that consolidation of diagnostics into the ResMed ecosystem will enhance network effects and customer stickiness, though the impact on profitability remains to be proven.

For those seeking a window into a durable, cash-generative healthcare franchise operating in chronic disease management, ResMed's 10-K presents a credible picture of steady execution. The valuation multiples and shareholder return posture suggest the market has already priced in this stability and expects continued mid-single-digit organic growth.